ChenGuang Biotech Group Co., Ltd. (SHE:300138)
China · Delayed Price · Currency is CNY 11.23
-0.06 (-0.53%)
May 7, 2026, 10:05 AM CST
ChenGuang Biotech Group Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 5,962 | 6,049 | 5,803 | 5,671 | 5,074 | 3,950 |
Other Revenue | 509.6 | 509.6 | 1,191 | 1,200 | 1,222 | 923.77 |
| 6,472 | 6,559 | 6,994 | 6,872 | 6,296 | 4,874 | |
Revenue Growth (YoY) | -7.26% | -6.22% | 1.79% | 9.14% | 29.18% | 24.55% |
Cost of Revenue | 5,667 | 5,735 | 6,535 | 6,072 | 5,452 | 4,175 |
Gross Profit | 804.23 | 824.38 | 459.36 | 799.37 | 843.87 | 698.53 |
Selling, General & Admin | 221.65 | 228.04 | 208.33 | 213.08 | 249.21 | 210.35 |
Research & Development | 157.79 | 166.24 | 128.6 | 97.4 | 129.03 | 94.79 |
Other Operating Expenses | 9.61 | 12.91 | -1.78 | 7.09 | 16.82 | 13.66 |
Operating Expenses | 393.95 | 412.09 | 335.27 | 318.45 | 395.16 | 319.48 |
Operating Income | 410.28 | 412.29 | 124.1 | 480.92 | 448.71 | 379.05 |
Interest Expense | -90.83 | -90.83 | -114.42 | -83.51 | -67.21 | -53.15 |
Interest & Investment Income | 76.42 | 84.81 | 58.36 | 104.28 | 63.27 | 39.58 |
Currency Exchange Gain (Loss) | -0.66 | -0.66 | 5.54 | 2.41 | 21.37 | -5.63 |
Other Non Operating Income (Expenses) | -7.15 | -3.41 | -34.03 | 3.31 | -2.36 | 7.61 |
EBT Excluding Unusual Items | 388.07 | 402.2 | 39.55 | 507.43 | 463.78 | 367.46 |
Gain (Loss) on Sale of Investments | 2.02 | 9.27 | -5.11 | 5.36 | -5.02 | 0.56 |
Gain (Loss) on Sale of Assets | -2.58 | 1.46 | 4.89 | -0.63 | 1.08 | 0.1 |
Asset Writedown | 1.08 | -6.94 | -0.46 | -1.1 | -1.32 | -10.91 |
Other Unusual Items | 31.88 | 31.88 | 68.08 | 44.76 | 43.24 | 40.85 |
Pretax Income | 420.47 | 437.87 | 106.95 | 555.82 | 501.76 | 398.07 |
Income Tax Expense | 58.38 | 62.99 | 28.99 | 61.65 | 65.67 | 47.47 |
Earnings From Continuing Operations | 362.09 | 374.88 | 77.96 | 494.17 | 436.09 | 350.6 |
Minority Interest in Earnings | -5.98 | -6 | 16.09 | -14.45 | -2.05 | 0.92 |
Net Income | 356.11 | 368.87 | 94.05 | 479.72 | 434.03 | 351.51 |
Net Income to Common | 356.11 | 368.87 | 94.05 | 479.72 | 434.03 | 351.51 |
Net Income Growth | 115.91% | 292.21% | -80.40% | 10.53% | 23.47% | 31.29% |
Shares Outstanding (Basic) | 483 | 483 | 517 | 532 | 533 | 529 |
Shares Outstanding (Diluted) | 483 | 483 | 517 | 532 | 533 | 529 |
Shares Change (YoY) | -4.35% | -6.62% | -2.76% | -0.14% | 0.80% | 4.13% |
EPS (Basic) | 0.74 | 0.76 | 0.18 | 0.90 | 0.81 | 0.67 |
EPS (Diluted) | 0.74 | 0.76 | 0.18 | 0.90 | 0.81 | 0.67 |
EPS Growth | 125.73% | 320.02% | -79.84% | 10.68% | 22.49% | 26.09% |
Free Cash Flow | -176.87 | 77.65 | -372.35 | -777.67 | 558.78 | -216.92 |
Free Cash Flow Per Share | -0.37 | 0.16 | -0.72 | -1.46 | 1.05 | -0.41 |
Dividend Per Share | 0.300 | 0.300 | 0.130 | 0.130 | 0.160 | 0.130 |
Dividend Growth | 130.77% | 130.77% | - | -18.75% | 23.08% | 30.00% |
Gross Margin | 12.43% | 12.57% | 6.57% | 11.63% | 13.40% | 14.33% |
Operating Margin | 6.34% | 6.29% | 1.77% | 7.00% | 7.13% | 7.78% |
Profit Margin | 5.50% | 5.62% | 1.34% | 6.98% | 6.89% | 7.21% |
Free Cash Flow Margin | -2.73% | 1.18% | -5.32% | -11.32% | 8.88% | -4.45% |
EBITDA | 596.78 | 594.82 | 290.76 | 633.47 | 593.27 | 509.67 |
EBITDA Margin | 9.22% | 9.07% | 4.16% | 9.22% | 9.42% | 10.46% |
D&A For EBITDA | 186.5 | 182.53 | 166.67 | 152.54 | 144.56 | 130.62 |
EBIT | 410.28 | 412.29 | 124.1 | 480.92 | 448.71 | 379.05 |
EBIT Margin | 6.34% | 6.29% | 1.77% | 7.00% | 7.13% | 7.78% |
Effective Tax Rate | 13.88% | 14.39% | 27.11% | 11.09% | 13.09% | 11.92% |
Revenue as Reported | 6,559 | 6,559 | 6,994 | 6,872 | 6,296 | 4,874 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.